General Information of Drug Off-Target (DOT) (ID: OTUYF0H3)

DOT Name ADP-ribose pyrophosphatase, mitochondrial (NUDT9)
Synonyms EC 3.6.1.13; ADP-ribose diphosphatase; ADP-ribose phosphohydrolase; Adenosine diphosphoribose pyrophosphatase; ADPR-PPase; Nucleoside diphosphate-linked moiety X motif 9; Nudix motif 9
Gene Name NUDT9
Related Disease
Endometrial carcinoma ( )
UniProt ID
NUDT9_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
1Q33; 1QVJ
EC Number
3.6.1.13
Pfam ID
PF00293
Sequence
MAGRLLGKALAAVSLSLALASVTIRSSRCRGIQAFRNSFSSSWFHLNTNVMSGSNGSKEN
SHNKARTSPYPGSKVERSQVPNEKVGWLVEWQDYKPVEYTAVSVLAGPRWADPQISESNF
SPKFNEKDGHVERKSKNGLYEIENGRPRNPAGRTGLVGRGLLGRWGPNHAADPIITRWKR
DSSGNKIMHPVSGKHILQFVAIKRKDCGEWAIPGGMVDPGEKISATLKREFGEEALNSLQ
KTSAEKREIEEKLHKLFSQDHLVIYKGYVDDPRNTDNAWMETEAVNYHDETGEIMDNLML
EAGDDAGKVKWVDINDKLKLYASHSQFIKLVAEKRDAHWSEDSEADCHAL
Function Hydrolyzes ADP-ribose (ADPR) to AMP and ribose 5'-phosphate.
Tissue Specificity Ubiquitously expressed but isoform 1 is the most predominant isoform.
KEGG Pathway
Purine metabolism (hsa00230 )
Metabolic pathways (hsa01100 )

Molecular Interaction Atlas (MIA) of This DOT

1 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Endometrial carcinoma DISXR5CY Strong Biomarker [1]
------------------------------------------------------------------------------------
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
7 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Ciclosporin DMAZJFX Approved Ciclosporin decreases the expression of ADP-ribose pyrophosphatase, mitochondrial (NUDT9). [2]
Acetaminophen DMUIE76 Approved Acetaminophen increases the expression of ADP-ribose pyrophosphatase, mitochondrial (NUDT9). [3]
Ivermectin DMDBX5F Approved Ivermectin decreases the expression of ADP-ribose pyrophosphatase, mitochondrial (NUDT9). [4]
Quercetin DM3NC4M Approved Quercetin decreases the expression of ADP-ribose pyrophosphatase, mitochondrial (NUDT9). [5]
Magnesium DMU4ORS Approved Magnesium increases the activity of ADP-ribose pyrophosphatase, mitochondrial (NUDT9). [6]
Deguelin DMXT7WG Investigative Deguelin increases the expression of ADP-ribose pyrophosphatase, mitochondrial (NUDT9). [7]
Manganese DMKT129 Investigative Manganese increases the activity of ADP-ribose pyrophosphatase, mitochondrial (NUDT9). [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Drug(s)

References

1 Differential expression of NUDT9 at different phases of the menstrual cycle and in different components of normal and neoplastic human endometrium.Taiwan J Obstet Gynecol. 2009 Jun;48(2):96-107. doi: 10.1016/S1028-4559(09)60266-7.
2 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
3 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
4 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
5 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
6 The specific, submicromolar-Km ADP-ribose pyrophosphatase purified from human placenta is enzymically indistinguishable from recombinant NUDT9 protein, including a selectivity for Mn2+ as activating cation and increase in Km for ADP-ribose, both elicited by H2O2. Biochim Biophys Acta. 2006 Oct;1760(10):1545-51. doi: 10.1016/j.bbagen.2006.06.003. Epub 2006 Jun 9.
7 Neurotoxicity and underlying cellular changes of 21 mitochondrial respiratory chain inhibitors. Arch Toxicol. 2021 Feb;95(2):591-615. doi: 10.1007/s00204-020-02970-5. Epub 2021 Jan 29.